Genmab A/S

Equities

GMAB

DK0010272202

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 06/02/2026 pm IST			5-day change	1st Jan Change
1,958.00 ^DKK	-1.48%		-3.17%	-3.40%

04/02	Goldman Sachs Lowers Price Target for Genmab to 1,793 Danish Kroner (from 1,880), Reiterates Neutral - BN	FW
04/02	Fitch Highlights Genmab's Antibody Oncology Leadership in Final Rating	MT

Transcript : Genmab A/S Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 03

Published on 01/14/2026 at 06:35 am IST - Modified on 01/14/2026 at 10:20 am IST

S&P Capital IQ

Presenter Speech
Zain Ebrahim (Analysts)

Good afternoon, everyone, and welcome to the Genmab presentation here at the 2026 JPMorgan Healthcare Conference. My name is Zain Ebrahim. I'm European pharma

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Genmab A/S

04/02	Goldman Sachs Lowers Price Target for Genmab to 1,793 Danish Kroner (from 1,880), Reiterates Neutral - BN	FW
04/02	Fitch Highlights Genmab's Antibody Oncology Leadership in Final Rating	MT
21/01	DNB Carnegie Upgrades Genmab to Buy, Raises PT	MT
21/01	Genmab Posts Higher Darzalex Net Sales in FY25	MT
21/01	Genmab Announces Net Sales of DARZALEX (daratumumab) for 2025	CI
21/01	Genmab: Darzalex Sales Reach Nearly $14.4 Billion in 2025 (Update)	FW
21/01	Genmab says net sales of Darzalex in 2025 $14,351 mln	RE
21/01	Genmab: Darzalex Sales Reach Nearly $14.4 Billion in 2025	FW
21/01	DNB Carnegie Upgrades Genmab to Buy (Hold), Raises Target Price to 2,235 Danish Kroner (from 1,985)	FW
20/01	BofA Lifts Genmab Price Target, Estimates on Expected 'Catalyst Rich' FY26	MT
19/01	SHB: Overreaction in the Market to Genmab's Epkinly Study	FW
19/01	Genmab's Phase 3 Study with Epcoritamab Fails to Meet Overall Survival Endpoint	FW
19/01	Genmab's Epcoritamab Improves Progression-free Survival in Lymphoma Patients, Phase 3 Data Shows	MT
17/01	Genmab A/S Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed Refractory Diffuse Large B-Cell Lymphoma	CI
17/01	AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma	CI
17/01	AbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival	DJ
17/01	Genmab Says Epcoritamab Improves Progression-Free Survival in Phase 3 Lymphoma Study	MT
17/01	Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study	RE
17/01	Genmab says phase 3 trial for epcoritamab did not reach statistical significance	RE
17/01	Genmab's blood cancer drug fails main goal in late-stage study	RE
16/01	Genmab Stock Trading Halted, Pending Material News Release	MT
15/01	Jyske Bank Raises Genmab Target Price to 2,300 Danish Kroner (2,000), Reiterates Hold - BN	FW
14/01	Genmab A/S Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 03:45 PM
08/01	UBS Raises Price Target for Genmab to 2,750 Danish Kroner (from 2,700), Reiterates Buy	FW
08/01	Genmab A/S Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence	CI